Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
February 10, 2008A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature.
While these findings are based on the study of ovarian-cancer cells from women with inherited mutations in the BRCA2 gene, they also may help explain the mechanics of cisplatin resistance in ovarian-cancer patients with BRCA1-gene mutations. Together such genetic mistakes are thought to cause about 10 percent of ovarian cancers, according to senior author Toshiyasu (Toshi) Taniguchi, M.D., Ph.D.
“Because BRCA1 and BRCA2 have similar functions in terms of DNA repair, we may be able to generalize these findings for women with either mutation,” said Taniguchi, an assistant member of the Hutchinson Center’s Human Biology and Public Health Sciences divisions.
BRCA2 works to repair damaged DNA; inherited mutations in this gene disrupt that ability, which increases the risk of ovarian and breast cancer. At the same time, such mutations also make cancer cells more vulnerable to DNA-damaging agents such as cisplatin and carboplatin. While ovarian tumors initially respond very well to platinum-based chemotherapy, eventually between 70 percent and 80 percent of advanced-stage ovarian-cancer patients develop a resistance to these drugs.
“The majority of advanced-stage ovarian-cancer patients die due to acquired resistance to platinum-based drugs. It is a serious problem,” he said.
Taniguchi and colleagues at the Hutchinson Center, University of Washington, Cedars-Sinai Medical Center and the Mayo Clinic have uncovered how such resistance occurs. They found that when exposed to cisplatin, some ovarian-cancer cells develop secondary mutations on their BRCA2 gene that restore the gene’s ability to repair DNA. This restoration of gene function then makes the cancer cells resistant to chemotherapy.
“This event is unlike any previous mechanism of resistance to chemotherapy identified in cancers,” said co-author Elizabeth Swisher, M.D., associate professor of medicine in the Department of Obstetrics and Gynecology and director of the Breast and Ovarian Cancer Prevention Program at the University of Washington. “By identifying the cause of chemotherapy resistance in these cancers, we may be able to better predict who will respond to different chemotherapy agents and find novel ways to re-sensitize tumors to chemotherapy that otherwise would not have had a good response to treatment.”
If women with recurrent ovarian cancer are found to have a secondary mutation on their BRCA2 gene, their cancer likely would be resistant not only to platinum-based compounds but also other drugs such as PARP inhibitors. “Testing whether relapsed tumors have a secondary mutation of BRCA2 may be important to predict clinical outcome,” Taniguchi said.
The researchers suspect they may be able to generalize their findings regarding secondary mutations in BRCA2 to other DNA-repair genes, such as BRCA1, which may help explain drug resistance to a variety of cancers, including those of the breast, prostate and pancreas.
Source: Fred Hutchinson Cancer Research Center
-
Researchers find important 'target' playing role in tobacco-related lung cancers
1 hour ago |
5 / 5 (1) |
0
-
'DIMming' cancer growth -- STAT: Diindolylmethane suppresses ovarian cancer
Jan 26, 2012 |
not rated yet |
1
-
Overcoming cancer drug resistance with nanoparticles
Jan 20, 2012 |
5 / 5 (2) |
0
-
Evolving ovarian cancer cells 'dodge' treatment with chemotherapy
Dec 20, 2011 |
not rated yet |
0
-
Scientists show how BRCA1 cancer gene mutations harm breast cells
Dec 14, 2011 |
not rated yet |
0
-
Fast photon control brings quantum photonic technologies closer
10 hours ago |
5 / 5 (4) |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (33) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (5) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Discovery paves way for salmonella vaccine
(Medical Xpress) -- An international research team led by a University of California, Davis, immunologist has taken an important step toward an effective vaccine against salmonella, a group of increasingly antibiotic-resistant ...
12 minutes ago |
5 / 5 (2) |
0
|
First-of-its-kind stem cell study re-grows healthy heart muscle in heart attack patients
Results from a Cedars-Sinai Heart Institute clinical trial show that treating heart attack patients with an infusion of their own heart-derived cells helps damaged hearts re-grow healthy muscle.
Medicine & Health / Cardiology
18 minutes ago |
5 / 5 (1) |
0
|
Ovarian cancer arises in fallopian tube of knockout mice
(Medical Xpress) -- The most deadly form of "ovarian" cancer arises in the fallopian tubes not the ovaries of knockout mice that lack two genes associated with the disease, said researchers led by Baylor College ...
13 minutes ago |
not rated yet |
0
|
Smoking bans lead to less, not more, smoking at home: study
Smoking bans in public/workplaces don't drive smokers to light up more at home, suggests a study of four European countries with smoke free legislation, published online in Tobacco Control.
18 minutes ago |
not rated yet |
0
UK cases of progressive sight loss condition set to rise a third by 2020
New cases of the progressive sight loss condition, known as age-related macular degeneration, or AMD for short, are set to rise by a third in the UK over the next decade, reveals research published online in the British Jo ...
17 minutes ago |
not rated yet |
0
Scientists discover reason for Mt. Hood's non-explosive nature
(PhysOrg.com) -- For a half-million years, Mount Hood has towered over the landscape, but unlike some of its cousins in Oregons Cascade Mountains and many other volcanoes around the Pacific Rim ...
Time of year important in projections of climate change effects on ecosystems
(PhysOrg.com) -- Does it matter whether long periods of hot weather, such as last year's heat wave that gripped the U.S. Midwest, happen in June or July, August or September?
Medical school link to wide variations in pass rate for specialist exam
Wide variations in doctors' pass rates, for a professional exam that is essential for one type of specialty training, seem to be linked to the particular medical school where the student graduated, indicates research published ...
Missing dark matter located: Intergalactic space is filled with dark matter
Researchers at the University of Tokyos Institute for the Physics and Mathematics of the Universe (IPMU) and Nagoya University used large-scale computer simulations and recent observational data of gravitational ...
Plants use circadian rhythms to prepare for battle with insects
In a study of the molecular underpinnings of plants' pest resistance, Rice University biologists have shown that plants both anticipate daytime raids by hungry insects and make sophisticated preparations to ...
Sensing self and non-self: New research into immune tolerance
At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually ...